OKLO has retraced to $49.27 this week — down 6% — yet the borrow market has done something unexpected: it has loosened meaningfully, reversing the tightening trend flagged in last week's note.
The shift in availability is the most interesting data point this week. Availability has climbed back to 72%, up from 29.9% just ten days ago and well above the mid-June range of 28–40% that had been signalling genuine squeeze pressure. That is a significant reversal. Cost to borrow ticked up 10% on the week to 0.74% — still historically low — but the directional tension has eased. Short interest itself has continued its slow retreat, now at 16.4% of the free float, down roughly 23% over the past month and marginally lower on the week. Bears are still covering, and unlike the previous week, the borrow pool is actually catching up with them rather than tightening beneath them. The ORTEX short score of 66.9 remains elevated — ranking in just the 5th percentile on short score and 4th percentile on availability rank across the universe — but the acute squeeze signal has softened.
Options positioning is calm. The put/call ratio sits at 0.64, fractionally below its 20-day average of 0.65, with a z-score near zero. That is about as neutral as it gets. Call demand remains dominant, consistent with the speculative premium still attached to OKLO's nuclear story, but there is no sign of either defensive hedging or unusual bullish loading ahead of the August 12 earnings date. The 52-week PCR high of 1.04 feels like a distant memory.
The founding team, however, keeps selling. On July 1, CEO and co-founder Jacob DeWitte sold 100,000 shares across two transactions for combined proceeds of roughly $5.3 million. Co-founder and COO Caroline Cochran sold 100,000 shares the same day for just over $5.2 million. CFO Richard Bealmear added another 16,321 shares to his June 1 sale, raising $859,000. All three also sold on June 1, when the stock was trading above $67. The 90-day net insider figure shows $45.9 million in net sales — a persistent and coordinated pattern of distribution from the top. Neither DeWitte nor Cochran has purchased shares in the data available. BlackRock added 1.1 million shares as of June 30, and Van Eck added 2.1 million, so institutional demand is absorbing some of that supply — but the insider-versus-institution dynamic is worth tracking closely.
The Street remains broadly divided. Most analysts are clustered around neutral — Guggenheim initiated at Neutral on June 25, UBS trimmed its target from $60 to $55 while staying neutral, and JP Morgan initiated at Neutral with an $83 target in May. The bulls are louder: Wedbush holds an Outperform at $110, Cantor Fitzgerald carries Overweight at $122, and Tigress Financial sits at Buy with a $130 target. With the stock at $49.27, those bull targets imply more than 100% upside — but the bear case around negative earnings, an unconventional business model, and limited HALEU fuel supply keeps the consensus rating pinned at Hold. The price-to-book of 4.0x has compressed sharply over 30 days alongside the stock's 16% monthly decline, and the EV/EBITDA of -55.5x reflects a company burning cash with no near-term path to profitability.
The next meaningful test is the August 12 earnings print. The last two quarterly results each produced a 11% one-day drop and a roughly 27–28% five-day slide — so the market has a clear pattern of punishing these releases. Whether loosening borrow availability and reduced short interest change that dynamic, or whether continued insider selling narrows the room for upside, is the tension worth watching into that date.
See the live data behind this article on ORTEX.
Open OKLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
